INTERPHEX 2025 is the premier global event for the pharmaceutical and biotechnology industries, bringing together industry professionals, exhibitors, and regulatory experts at the Javits Center in New York City from April 1-3, 2025. As a leader in advanced manufacturing and bioprocessing solutions, INTERPHEX fosters partnerships, showcases innovative solutions, and delivers valuable insights into the latest advancements in drug development, biopharmaceutical production, and automation. The event’s conference program and learning labs provide industry-leading education, addressing challenges in formulation, scalability, and ensuring access to innovative medicines.
Federal Equipment Company is proud to participate in INTERPHEX 2025, offering an extensive inventory of biopharmaceutical and pharmaceutical manufacturing technologies that align with the event’s focus on cutting-edge advancements and commercialization strategies. Our expertise in providing pre-owned equipment enables manufacturers to enhance their manufacturing processes, cleanroom operations, and drug delivery systems with cost-effective, high-quality solutions.
Supporting Biopharma and Pharma Innovation with Proven Equipment Solutions
At Federal Equipment Company, we specialize in equipping biotech and pharmaceutical manufacturers with the machinery they need to scale up production, optimize bioprocessing, and streamline drug product development. Our extensive inventory covers a wide range of biotechnology equipment categories, including:
- Bioreactors & Fermenters – Essential for biopharmaceutical production, including gene therapy, cell culture, and single-use processing.
- Centrifuges – Critical for protein purification, cell harvesting, and separation applications in biopharma and drug development.
- Chromatography Equipment – Supporting high-purity drug substance production with advanced separation and purification technologies.
- Freeze Dryers (Lyophilizers) – Ensuring the stability and scalability of dosage forms in drug formulation and commercialization.
Fueling Scalability and Innovation at INTERPHEX 2025
As the pharma and biotech industries continue to evolve, automation, sustainability, and supply chain resilience are critical factors in ensuring access to innovative medicines. Federal Equipment Company helps manufacturers navigate these challenges by providing cost-effective, high-quality manufacturing technologies that reduce lead times, enhance bioprocessing efficiency, and facilitate clinical trials to commercial production. Our expertise in pharmaceutical industry advancements ensures that businesses can implement breakthrough manufacturing solutions without excessive capital investment.
Visit Us at INTERPHEX 2025
Stop by booth #3109 at Interphex 2025, held at the Javits Center in New York City from April 1-3, 2025, to discuss your equipment needs. We have on-hand inventory in more than 200 categories, where you can source reliable pharmaceutical processing and packaging equipment. Much of our inventory comes from asset management programs with large multinational companies, giving you a wide range of options to acquire leading OEM brand equipment from reputable sources. This ensures rapid installation and operation, helping you accelerate your manufacturing processes and reduce time to market.
Our leadership team, including President Adam Covitt, Director of Latin American Operations Orlando Martinez, Executive Vice President Justin Kadis, and Techceuticals Technical Director Jesus Lopez, will be in attendance at our booth. They will be available to discuss how our solutions can support your container closure integrity testing, pharmaceutical packaging, and overall processing needs.
Have surplus equipment to sell? We would like to discuss this with you. Please stop by our booth and let us know what you would like to sell.
No matter what your equipment needs are, make Federal Equipment Company your first call. Explore our inventory today at Biotechnology Equipment – Used Pharmaceutical Equipment | Federal Equipment Company and enhance your Biopharma strategy.
